ZA200600151B - Quil A fraction with low toxicity and use thereof - Google Patents

Quil A fraction with low toxicity and use thereof Download PDF

Info

Publication number: ZA200600151B
Authority: ZA; South Africa
Prior art keywords: quil; adjuvant; fraction; iscom; composition
Prior art date: 2003-07-07

Application number

ZA200600151A

Other languages

English (en)

Inventor

Morein Bror

Ekstroem Jill

Loevgren Bengtsson Karin

Ranlund Katarina

Original Assignee

Isconova Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-07

Filing date

2006-01-06

Publication date

2007-01-31

2006-01-06 Application filed by Isconova Ab filed Critical Isconova Ab

2007-01-31 Publication of ZA200600151B publication Critical patent/ZA200600151B/en

Links

UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 title claims description 67
231100000053 low toxicity Toxicity 0.000 title description 5
239000011159 matrix material Substances 0.000 claims description 150
239000002671 adjuvant Substances 0.000 claims description 94
239000000203 mixture Substances 0.000 claims description 83
239000002245 particle Substances 0.000 claims description 56
102000009016 Cholera Toxin Human genes 0.000 claims description 54
108010049048 Cholera Toxin Proteins 0.000 claims description 54
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 53
210000003918 fraction a Anatomy 0.000 claims description 34
238000000034 method Methods 0.000 claims description 31
229930182490 saponin Natural products 0.000 claims description 26
150000007949 saponins Chemical class 0.000 claims description 26
235000017709 saponins Nutrition 0.000 claims description 26
239000000126 substance Substances 0.000 claims description 25
230000002519 immonomodulatory effect Effects 0.000 claims description 22
239000012634 fragment Substances 0.000 claims description 18
239000001397 quillaja saponaria molina bark Substances 0.000 claims description 17
238000011282 treatment Methods 0.000 claims description 16
230000002195 synergetic effect Effects 0.000 claims description 15
230000028993 immune response Effects 0.000 claims description 14
235000009001 Quillaja saponaria Nutrition 0.000 claims description 13
210000002196 fr. b Anatomy 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
241000588832 Bordetella pertussis Species 0.000 claims description 9
241001092142 Molina Species 0.000 claims description 9
239000003053 toxin Substances 0.000 claims description 9
231100000765 toxin Toxicity 0.000 claims description 9
108700012359 toxins Proteins 0.000 claims description 9
241001454523 Quillaja saponaria Species 0.000 claims description 8
210000000540 fraction c Anatomy 0.000 claims description 7
230000001580 bacterial effect Effects 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
231100000699 Bacterial toxin Toxicity 0.000 claims description 3
108010039939 Cell Wall Skeleton Proteins 0.000 claims description 3
241000588724 Escherichia coli Species 0.000 claims description 3
108010002350 Interleukin-2 Proteins 0.000 claims description 3
108010028921 Lipopeptides Proteins 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
239000000688 bacterial toxin Substances 0.000 claims description 3
229920001400 block copolymer Polymers 0.000 claims description 3
210000004520 cell wall skeleton Anatomy 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000002955 immunomodulating agent Substances 0.000 claims description 3
229940121354 immunomodulator Drugs 0.000 claims description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
241000894007 species Species 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
241000699670 Mus sp. Species 0.000 description 79
108010058846 Ovalbumin Proteins 0.000 description 61
229940092253 ovalbumin Drugs 0.000 description 61
229960000814 tetanus toxoid Drugs 0.000 description 57
230000004044 response Effects 0.000 description 50
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
238000009472 formulation Methods 0.000 description 37
238000002649 immunization Methods 0.000 description 36
230000005875 antibody response Effects 0.000 description 34
239000000427 antigen Substances 0.000 description 33
108091007433 antigens Proteins 0.000 description 33
102000036639 antigens Human genes 0.000 description 33
229960005486 vaccine Drugs 0.000 description 31
230000000694 effects Effects 0.000 description 20
241000725643 Respiratory syncytial virus Species 0.000 description 19
210000004027 cell Anatomy 0.000 description 17
238000002474 experimental method Methods 0.000 description 14
210000002966 serum Anatomy 0.000 description 13
210000004989 spleen cell Anatomy 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
238000002965 ELISA Methods 0.000 description 11
230000010261 cell growth Effects 0.000 description 11
PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
238000007912 intraperitoneal administration Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
230000037452 priming Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
230000003053 immunization Effects 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
238000007920 subcutaneous administration Methods 0.000 description 9
231100000331 toxic Toxicity 0.000 description 9
230000002588 toxic effect Effects 0.000 description 9
230000000240 adjuvant effect Effects 0.000 description 8
238000013401 experimental design Methods 0.000 description 8
244000052769 pathogen Species 0.000 description 8
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
238000010828 elution Methods 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
241001092473 Quillaja Species 0.000 description 5
241000700605 Viruses Species 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000000897 modulatory effect Effects 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
210000003501 vero cell Anatomy 0.000 description 5
PIGTXFOGKFOFTO-PPEDVFHSSA-N CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O Chemical compound CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O PIGTXFOGKFOFTO-PPEDVFHSSA-N 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
238000011785 NMRI mouse Methods 0.000 description 3
238000003349 alamar blue assay Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002101 lytic effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
229910018626 Al(OH) Inorganic materials 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
241000711920 Human orthopneumovirus Species 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
102100021696 Syncytin-1 Human genes 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
229940024545 aluminum hydroxide Drugs 0.000 description 2
244000309466 calf Species 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012636 effector Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011894 semi-preparative HPLC Methods 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
229940124873 Influenza virus vaccine Drugs 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000219287 Saponaria Species 0.000 description 1
208000020967 Sever disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000008102 immune modulation Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002766 immunoenhancing effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)

ZA200600151A 2003-07-07 2006-01-06 Quil A fraction with low toxicity and use thereof ZA200600151B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0301998A SE0301998D0 (sv)	2003-07-07	2003-07-07	Quil A fraction with low toxicity and use thereof

Publications (1)

Publication Number	Publication Date
ZA200600151B true ZA200600151B (en)	2007-01-31

Family

ID=27731119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200600151A ZA200600151B (en)	2003-07-07	2006-01-06	Quil A fraction with low toxicity and use thereof

Country Status (15)

Country	Link
US (8)	US8821881B2 (fr)
EP (1)	EP1648505B1 (fr)
JP (1)	JP4731475B2 (fr)
AT (1)	ATE442164T1 (fr)
AU (1)	AU2004254152B2 (fr)
BR (1)	BRPI0412444B8 (fr)
CA (1)	CA2529363C (fr)
DE (1)	DE602004023089D1 (fr)
DK (1)	DK1648505T3 (fr)
ES (1)	ES2331952T3 (fr)
NZ (1)	NZ544299A (fr)
PL (1)	PL1648505T3 (fr)
SE (1)	SE0301998D0 (fr)
WO (1)	WO2005002620A1 (fr)
ZA (1)	ZA200600151B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1104306E (pt) *	1998-08-10	2006-05-31	Antigenics Inc	Composicoes de cpg e adjuvantes de saponina e seus metodos
SE0202110D0 (sv) *	2002-07-05	2002-07-05	Isconova Ab	Iscom preparation and use thereof
SE0301998D0 (sv)	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
US8007806B2 (en)	2005-01-20	2011-08-30	Isconova Ab	Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (fr) *	2005-09-16	2007-03-21	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine
CN101448523A (zh)	2006-03-24	2009-06-03	诺华疫苗和诊断有限两合公司	无需冷藏储存流感疫苗
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
EP1902727A1 (fr) *	2006-09-22	2008-03-26	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine
WO2008031878A1 (fr) *	2006-09-15	2008-03-20	Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH	Composition pour la thérapie et/ou pour la prophylaxie d'infections au vhb et de maladies dont la médiation est assurée par le vhb
DK2094278T3 (en) *	2006-11-20	2017-07-24	Duecom	USE OF LIPID-CONTAINING PARTICLES INCLUDING QUILLAJA SAPONINS FOR CANCER TREATMENT
KR20100045437A (ko)	2007-06-27	2010-05-03	노파르티스 아게	첨가물이 적은 인플루엔자 백신
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2569907T3 (es)	2008-06-27	2016-05-13	Zoetis Services Llc	Composiciones adyuvantes novedosas
CN102470168A (zh) *	2009-07-10	2012-05-23	伊斯克诺瓦公司	新组合物
US8771709B2 (en)	2010-09-20	2014-07-08	Crucell Holland B.V.	Therapeutic vaccination against active Tuberculosis
DK2750683T4 (da) *	2011-10-03	2021-04-12	Croda Int Plc	Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
EP3566714A1 (fr)	2011-11-28	2019-11-13	Janssen Vaccines & Prevention B.V.	Vaccins contre la grippe et utilisations associées
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl)	2012-03-12	2016-08-31	Crucell Holland B.V.	Šarže rekombinantnega adenovirusa s spremenjenimi konci
JP5805908B2 (ja)	2012-03-22	2015-11-10	クルセルホランドベーヴェー	Ｒｓｖに対するワクチン
US9119813B2 (en)	2012-03-22	2015-09-01	Crucell Holland B.V.	Vaccine against RSV
US11576958B2 (en)	2013-02-07	2023-02-14	Children's Medical Center Corporation	Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014135651A1 (fr)	2013-03-08	2014-09-12	Crucell Holland B.V.	Vaccin acellulaire contre la coqueluche
AR095962A1 (es)	2013-04-01	2015-11-25	Moreinx Ab	Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
KR102236497B1 (ko)	2013-04-25	2021-04-06	얀센 백신스 앤드 프리벤션 비.브이.	안정화된 가용성 예비융합 ｒｓｖｆ 폴리펩타이드
EA034639B1 (ru)	2013-05-30	2020-03-02	Янссен Вэксинс Энд Превеншн Б.В.	Вакцины против вируса гриппа и их применения
CN105408348B (zh)	2013-06-17	2021-07-06	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f多肽
WO2015000831A1 (fr)	2013-07-02	2015-01-08	Crucell Holland B.V.	Procédé pour la préparation de virosomes
WO2015000832A1 (fr)	2013-07-02	2015-01-08	Crucell Holland B.V.	Procédé de préparation de virosomes
UA130246C2 (uk)	2013-09-19	2025-12-31	Зоетіс Сервісіз Ллс	Ад'ювант на основі олії
DE102014005771A1 (de)	2014-04-23	2015-10-29	Clariant International Ltd.	Verwendung von wässrigen driftreduzierenden Zusammensetzungen
MX378904B (es)	2014-07-10	2025-03-10	Janssen Vaccines & Prevention Bv	Vacunas para virus influenza y usos de las mismas.
RS58080B1 (sr)	2014-11-04	2019-02-28	Janssen Vaccines & Prevention Bv	Terapeutske vakcine protiv hpv16
CN115317600A (zh)	2015-01-16	2022-11-11	硕腾服务有限责任公司	口蹄疫疫苗
JP6735288B2 (ja)	2015-04-14	2020-08-05	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
EA039065B1 (ru)	2015-07-07	2021-11-29	Янссен Вэксинс Энд Превеншн Б.В.	Вакцина против rsv
US10457708B2 (en)	2015-07-07	2019-10-29	Janssen Vaccines & Prevention B.V.	Stabilized soluble pre-fusion RSV F polypeptides
JP6470872B2 (ja)	2015-08-20	2019-02-13	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	治療用ｈｐｖ１８ワクチン
US10538557B2 (en)	2015-09-02	2020-01-21	Janssen Vaccines & Prevention B.V.	Stabilized viral class I fusion proteins
CA2996007A1 (fr)	2015-09-03	2017-03-09	Novavax, Inc.	Compositions vaccinales ayant une stabilite et une immunogenicite ameliorees
RU2723039C2 (ru)	2015-12-23	2020-06-08	Пфайзер Инк.	Мутанты белка f rsv
JP7233928B2 (ja)	2016-04-05	2023-03-07	ヤンセンファッシンズアンドプリベンションベーフェー	Ｒｓｖに対するワクチン
IL262108B2 (en)	2016-04-05	2023-04-01	Janssen Vaccines Prevention B V	Soluble pre-fusion rsv f proteins are stabilized
JP7053491B2 (ja)	2016-05-02	2022-04-12	ヤンセンファッシンズアンドプリベンションベーフェー	治療用ｈｐｖワクチン組み合わせ
DE202016003070U1 (de)	2016-05-09	2016-06-07	Clariant International Ltd.	Stabilisatoren für Silikatfarben
CN109154000B (zh)	2016-05-12	2022-07-05	扬森疫苗与预防公司	有效和平衡的双向启动子
WO2017207477A1 (fr)	2016-05-30	2017-12-07	Janssen Vaccines & Prevention B.V.	Protéines f du vrs de pré-fusion solubles stabilisées
CN109311946A (zh)	2016-05-30	2019-02-05	扬森疫苗与预防公司	稳定化的融合前rsv f蛋白
RU2745500C2 (ru)	2016-06-20	2021-03-25	Янссен Вэксинс Энд Превеншн Б.В.	Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (fr)	2016-07-14	2018-01-18	Janssen Vaccines & Prevention B.V.	Vaccins contre le hpv
CN109906411B (zh)	2016-11-04	2022-12-27	卡博特公司	含结晶聚酯和有机硅的纳米复合物
US11034978B2 (en)	2017-02-09	2021-06-15	Janssen Vaccines & Prevention B.V.	Potent and short promoter for expression of heterologous genes
AU2018267971A1 (en)	2017-05-17	2019-11-07	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against RSV infection
JP7317796B2 (ja)	2017-07-24	2023-07-31	ノババックス，インコーポレイテッド	呼吸器疾患を治療するための方法および組成物
SG11202001458SA (en)	2017-09-15	2020-03-30	Janssen Vaccines & Prevention Bv	Method for the safe induction of immunity against rsv
LT3743106T (lt)	2018-01-23	2022-09-26	Janssen Vaccines & Prevention B.V.	Gripo viruso vakcinos ir jų panaudojimo būdai
CN120227451A (zh)	2018-03-19	2025-07-01	诺瓦瓦克斯股份有限公司	多价流感纳米颗粒疫苗
GB201807303D0 (en)	2018-05-03	2018-06-20	London School Of Hygeine & Tropical Medicine	Glyconjugate vaccines
CA3098103A1 (fr)	2018-05-23	2019-11-28	Adc Therapeutics Sa	Adjuvant moleculaire
MX2021005607A (es)	2018-11-13	2021-06-30	Janssen Vaccines & Prevention Bv	Proteinas f de prefusion del vrs estabilizadas.
US20220204567A1 (en)	2019-04-25	2022-06-30	Janssen Vaccines & Prevention B.V.	Recombinant influenza antigens
JP2022532742A (ja)	2019-05-15	2022-07-19	ヤンセンファッシンズアンドプリベンションベーフェー	アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
WO2020229577A1 (fr)	2019-05-15	2020-11-19	Janssen Vaccines & Prevention B.V.	Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
CA3152957A1 (fr)	2019-09-05	2021-03-11	Janssen Vaccines & Prevention B.V.	Vaccins contre le virus de la grippe et leurs utilisations
US10953089B1 (en)	2020-01-27	2021-03-23	Novavax, Inc.	Coronavirus vaccine formulations
JP2023512519A (ja)	2020-01-31	2023-03-27	ベスイスラエルディーコネスメディカルセンターインコーポレイテッド	コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
KR20230009466A (ko)	2020-05-11	2023-01-17	얀센 파마슈티칼즈, 인코포레이티드	SARS-CoV-2 백신
CA3183086A1 (fr)	2020-05-11	2021-11-18	Janssen Pharmaceuticals, Inc.	Proteines de fusion de proteine de spicule de coronavirus stabilisees
WO2021229448A1 (fr)	2020-05-11	2021-11-18	Janssen Pharmaceuticals, Inc.	Réplicon d'arn codant pour une protéine de spicule de coronavirus stabilisée
US20230233661A1 (en)	2020-06-29	2023-07-27	Janssen Vaccines & Prevention B.V.	Vaccine combination against repiratory syncytial virus infection
US20230302119A1 (en)	2020-07-06	2023-09-28	Janssen Pharmaceuticals, Inc.	Stabilized Corona Virus Spike Protein Fusion Proteins
JP7822149B2 (ja)	2020-10-02	2026-03-02	ファイザー・インク	Ｒｓｖｆタンパク質生産のための細胞培養工程
WO2022175479A1 (fr)	2021-02-19	2022-08-25	Janssen Vaccines & Prevention B.V.	Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial
WO2022175477A1 (fr)	2021-02-19	2022-08-25	Janssen Vaccines & Prevention B.V.	Antigènes fb de vrs de pré-fusion stabilisés
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
KR20230165275A (ko)	2021-04-01	2023-12-05	얀센 백신스 앤드 프리벤션 비.브이.	안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (fr)	2021-08-17	2023-02-23	Janssen Pharmaceuticals, Inc.	Vaccins contre le sars-cov-2
WO2023047348A1 (fr)	2021-09-24	2023-03-30	Janssen Pharmaceuticals, Inc.	Protéines de fusion de protéine de spicule de coronavirus stabilisées
WO2023047349A1 (fr)	2021-09-24	2023-03-30	Janssen Pharmaceuticals, Inc.	Protéines de fusion protéines de spicule de coronavirus stabilisées
WO2023111725A1 (fr)	2021-12-14	2023-06-22	Janssen Pharmaceuticals, Inc.	Vaccins anti-sars-cov-2
EP4448802A1 (fr)	2021-12-16	2024-10-23	Janssen Vaccines & Prevention B.V.	Protéines de fusion hmpv pré-hybrides stabilisées
WO2023196634A2 (fr)	2022-04-08	2023-10-12	Flagship Pioneering Innovations Vii, Llc	Vaccins et procédés associés
KR20250010642A (ko)	2022-05-12	2025-01-21	엠에스디 인터내셔널 비즈니스 게엠베하	안정화된 융합-전 hmpv 융합 단백질
WO2024017682A1 (fr)	2022-07-18	2024-01-25	Janssen Vaccines & Prevention B.V.	Immunogènes du vrs
EP4565604A2 (fr)	2022-08-01	2025-06-11	Flagship Pioneering Innovations VII, LLC	Protéines immunomodulatrices et méthodes associées
WO2024061757A1 (fr)	2022-09-23	2024-03-28	Janssen Vaccines & Prevention B.V.	Protéines f du piv1 humain en pré-fusion
WO2024061759A1 (fr)	2022-09-23	2024-03-28	Janssen Vaccines & Prevention B.V.	Protéines s de coronavirus stabilisées
WO2024061753A1 (fr)	2022-09-23	2024-03-28	Janssen Vaccines & Prevention B.V.	Protéines de fusion de classe i trimères stabilisées
WO2024074584A1 (fr)	2022-10-06	2024-04-11	Janssen Vaccines & Prevention B.V.	Protéines f du piv3 sous forme pré-fusion stabilisées
CN120202213A (zh)	2022-11-14	2025-06-24	扬森疫苗与预防有限公司	乙型流感病毒疫苗及其用途
WO2024151583A2 (fr)	2023-01-09	2024-07-18	Flagship Pioneering Innovations Vii, Llc	Vaccins et procédés associés
US20240252614A1 (en)	2023-01-18	2024-08-01	Pfizer Inc.	Vaccines against respiratory diseases
WO2024167885A1 (fr)	2023-02-06	2024-08-15	Flagship Pioneering Innovations Vii, Llc	Compositions immunomodulatrices et procédés associés
KR20250152090A (ko)	2023-02-21	2025-10-22	엠에스디 인터내셔널 비즈니스 게엠베하	이종 삼량체화 도메인이 없는 안정화된 삼량체 rsv 융합 단백질
WO2024258829A1 (fr)	2023-06-12	2024-12-19	Flagship Pioneering Innovations Vii, Llc	Compositions de vaccin contre le sars-cov-2 et procédés associés
TW202545974A (zh)	2024-01-26	2025-12-01	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	免疫受體抑制蛋白及相關方法
WO2025163460A2 (fr)	2024-01-30	2025-08-07	Pfizer Inc.	Vaccins contre des maladies respiratoires
US20250353881A1 (en)	2024-05-16	2025-11-20	Flagship Pioneering Innovations Vii, Llc	Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (fr)	2024-05-22	2025-11-27	Flagship Pioneering Innovations Vii, Llc	Protéines de ciblage d'immunorécepteurs et procédés associés
WO2026018181A1 (fr)	2024-07-17	2026-01-22	Pfizer Inc.	Compositions immunogènes et leurs utilisations
WO2026038177A1 (fr)	2024-08-16	2026-02-19	Pfizer Inc.	Compositions immunogènes et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5839376B2 (ja) *	1978-10-30	1983-08-30	富士通株式会社	イオン注入法
SE8205892D0 (sv)	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE71303T1 (de)	1986-01-14	1992-01-15	Nederlanden Staat	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
CA1331443C (fr)	1987-05-29	1994-08-16	Charlotte A. Kensil	Adjuvant a saponine
NZ230747A (en) *	1988-09-30	1992-05-26	Bror Morein	Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl)	1990-10-23	1992-05-18	Nederlanden Staat	Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
SE9600647D0 (sv)	1996-02-21	1996-02-21	Bror Morein	Ny användning
US6231859B1 (en)	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
AUPO517897A0 (en)	1997-02-19	1997-04-11	Csl Limited	Chelating immunostimulating complexes
US6558670B1 (en) *	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
SE0202110D0 (sv)	2002-07-05	2002-07-05	Isconova Ab	Iscom preparation and use thereof
SE0301998D0 (sv)	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof

2003
- 2003-07-07 SE SE0301998A patent/SE0301998D0/xx unknown
2004
- 2004-07-07 BR BRPI0412444A patent/BRPI0412444B8/pt active IP Right Grant
- 2004-07-07 EP EP04749076A patent/EP1648505B1/fr not_active Expired - Lifetime
- 2004-07-07 ES ES04749076T patent/ES2331952T3/es not_active Expired - Lifetime
- 2004-07-07 WO PCT/SE2004/001038 patent/WO2005002620A1/fr not_active Ceased
- 2004-07-07 JP JP2006518582A patent/JP4731475B2/ja not_active Expired - Lifetime
- 2004-07-07 AT AT04749076T patent/ATE442164T1/de not_active IP Right Cessation
- 2004-07-07 PL PL04749076T patent/PL1648505T3/pl unknown
- 2004-07-07 CA CA2529363A patent/CA2529363C/fr not_active Expired - Lifetime
- 2004-07-07 DE DE602004023089T patent/DE602004023089D1/de not_active Expired - Lifetime
- 2004-07-07 US US10/562,866 patent/US8821881B2/en active Active
- 2004-07-07 NZ NZ544299A patent/NZ544299A/en not_active IP Right Cessation
- 2004-07-07 AU AU2004254152A patent/AU2004254152B2/en not_active Expired
- 2004-07-07 DK DK04749076T patent/DK1648505T3/da active
2006
- 2006-01-06 ZA ZA200600151A patent/ZA200600151B/en unknown
2014
- 2014-07-29 US US14/445,690 patent/US20140335049A1/en not_active Abandoned
2015
- 2015-05-18 US US14/714,664 patent/US20150320858A1/en not_active Abandoned
2016
- 2016-02-26 US US15/054,801 patent/US20160184427A1/en not_active Abandoned
2018
- 2018-01-18 US US15/874,262 patent/US20180369368A1/en not_active Abandoned
2019
- 2019-12-03 US US16/701,948 patent/US20200345840A1/en not_active Abandoned
2021
- 2021-09-17 US US17/477,739 patent/US20220241408A1/en not_active Abandoned
2023
- 2023-10-04 US US18/376,666 patent/US12171828B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20150320858A1 (en)	2015-11-12
DK1648505T3 (da)	2009-12-21
PL1648505T3 (pl)	2010-02-26
ATE442164T1 (de)	2009-09-15
US20220241408A1 (en)	2022-08-04
US20160184427A1 (en)	2016-06-30
CA2529363A1 (fr)	2005-01-13
JP4731475B2 (ja)	2011-07-27
BRPI0412444B1 (pt)	2016-06-14
US8821881B2 (en)	2014-09-02
AU2004254152A1 (en)	2005-01-13
US20200345840A1 (en)	2020-11-05
US12171828B2 (en)	2024-12-24
SE0301998D0 (sv)	2003-07-07
EP1648505A1 (fr)	2006-04-26
BRPI0412444A (pt)	2006-09-19
ES2331952T3 (es)	2010-01-21
DE602004023089D1 (de)	2009-10-22
US20140335049A1 (en)	2014-11-13
WO2005002620A1 (fr)	2005-01-13
AU2004254152B2 (en)	2009-10-29
JP2007527386A (ja)	2007-09-27
US20060239963A1 (en)	2006-10-26
EP1648505B1 (fr)	2009-09-09
US20240024468A1 (en)	2024-01-25
NZ544299A (en)	2009-03-31
US20180369368A1 (en)	2018-12-27
CA2529363C (fr)	2013-04-02
BRPI0412444B8 (pt)	2021-05-25

Publication	Publication Date	Title
US12171828B2 (en)	2024-12-24	Quil A fraction with low toxicity and use thereof
US6146632A (en)	2000-11-14	Vaccines
US10813994B2 (en)	2020-10-27	Composition comprising iscom particles and live micro-organisms
AU2016341619B2 (en)	2020-01-02	New adjuvant and vaccine composition containing the same
AU687494C (en)	1998-10-29	Vaccines
HK1021504B (en)	2005-03-18	Vaccines comprising oil/water emulsion with tocopherol and squalene
HK1012243B (en)	2000-05-12	Vaccines